| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Stephens & Co. analyst Jeff Garro maintains Veradigm (OTC:MDRX) with a Equal-Weight and raises the price target from $7 ...
https://www.axios.com/pro/health-tech-deals/2024/11/10/mckesson-oracle-veradigm-bidders-allscripts
TD Cowen analyst Charles Rhyee maintains Veradigm (OTC:MDRX) with a Buy and lowers the price target from $26 to $15.
Deutsche Bank analyst George Hill downgrades Veradigm (OTC:MDRX) from Buy to Hold and lowers the price target from $15 to $10.
Veradigm will be suspended from the Nasdaq Stock Market on February 29 due to non-compliance with NASDAQ listing rules and is n...
The transaction will be funded through cash on hand and is not subject to a financing condition. The purchase price to be paid ...
The Company also announced that its Board of Directors has unanimously adopted a limited duration stockholder rights plan in an...